When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...